The World Health Organization (WHO) on Tuesday, May 28, gave the green light to a draft resolution that signals member countries are preparing to push for more transparency in drug pricing, Reuters reports.
According to the report, the resolution approved did not include rules requiring pharmaceutical companies to disclose manufacturing costs.
MSF’s Gaelle Krikorian said that while the resolution was a “welcome first step,” drug companies should be forced to reveal more.
“We need to know the mark-ups corporations charge, production costs, the cost of clinical trials, how much investment is really covered by companies, and how much is underwritten by taxpayers and non-profit groups,” she told Reuters.
